skip to the content

References: approaches to VEGF inhibition

  1. Hicklin DJ, Ellis LM. J Clin Oncol 2005;23:1011–27.
  2. Jain RK, Duda DG, Clark JW, Loeffler JS. Nat Clin Pract Oncol 2006;3:24–40.
  3. Baka S, Clamp AR, Jayson GC. Expert Opin Ther Targets 2006;10:867–76.
  4. Presta LG, Chen H, O'Connor SJ, et al. Cancer Res 1997;57:4593–9.
  5. Morabito A, De Maio E, Di Maio M, et al. Oncologist 2006;11:753–64.
  6. Kerbel RS. Science 2006;312:1171–5.
  7. Verheul HM. Nat Rev Cancer 2007;7:475–85.
  8. Willett CG, Boucher Y, di Tomaso E, et al. Nat Med 2004;10:145–47.
  9. Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Cancer Res 1996;56:4032–9.
  10. Borgström P, Bourdon MA, Hillan KJ, et al. Prostate 1998;35:1–10.
  11. Yuan F, Chen YI, Dellian M, et al. Proc Natl Acad Sci USA 1996;93:14765–70.
  12. Lee CG, Heijn M, di Tomaso E, et al. Cancer Res 2000;60:5565–70.
  13. Inai T, Mancuso M, Hashizume H, et al. Am J Pathol.2004;165:35–52.
  14. Tong RT, Boucher Y, Kozin SV, et al. Cancer Res 2004;64:3731–6.
  15. Jain RK. Nat Med 2001;7:987–9.
  16. Jain RK. Science 2005;307:58–62.
  17. Warren RS, Yuan H, Matli MR, et al. J Clin Invest 1995;95:1789–97.
  18. Garcia-Albeniz X. Targ Oncol 2007;2:241–52.
  19. Gerber HP, Ferrara N. Cancer Res 2005;65:671–80.
  20. Folkman J. In: DeVita VT, Hellman SMD, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 2865–82.
  21. Sweeney CJ, Miller KD, Sledge GW. Trends Mol Med 2003;9:24–9.
  22. Herbst RS. Expert Opin Emerging Drugs 2006;11:635–50.